Lizhu Group: Application for market authorization of Lekang Qitai monoclonal antibody injection accepted.

On December 25th, LIZHU Group announced that its holding subsidiary, Zhuhai LIZHU Monoclonal Antibody Biotechnology Co., Ltd., has received a "Notice of Acceptance" issued by the National Medical Products Administration recently. The domestic production drug registration and listing application for "LAIKANGQITA monoclonal antibody injection" jointly developed by LIZHU Monoclonal Antibody and Beijing Xinkanghe Biology Medicine Technology Co., Ltd. has been accepted by the National Medical Products Administration. LAIKANGQITA monoclonal antibody injection is intended for adult patients with moderate to severe plaque psoriasis who are suitable for systemic treatment or phototherapy.